Obesity Clinical Trials in Birmingham, Alabama

18 studies are recruiting for obesity in Birmingham, Alabama right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

    This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection frac…

    Stage
    Phase 3
    Ages
    18 to 99
    Site
    University of Alabama Saint Vincent's Birmingham, Birmingham, Alabama
    Locations
    657 in total
    Run by
    Amgen

    See if you can join NCT07037459 on ClinicalTrials.gov

  2. A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

    Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    AURORA-2 Clinical Site, Birmingham, Alabama
    Locations
    135 in total
    Run by
    Ascletis Pharma (China) Co., Limited

    See if you can join NCT07743450 on ClinicalTrials.gov

  3. A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

    Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight wit…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    AURORA-1 Clinical Site, Birmingham, Alabama
    Locations
    122 in total
    Run by
    Ascletis Pharma (China) Co., Limited

    See if you can join NCT07743463 on ClinicalTrials.gov

  4. A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

    This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatmen…

    Stage
    Phase 3
    Ages
    18 to 79
    Site
    ACCOMPLISH-2 Research Site, Birmingham, Alabama
    Locations
    74 in total
    Run by
    Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

    See if you can join NCT07654374 on ClinicalTrials.gov

  5. Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

    The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be u…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Uni of Alabama at Birmingham, Birmingham, Alabama
    Locations
    62 in total
    Run by
    Novo Nordisk A/S

    See if you can join NCT07770841 on ClinicalTrials.gov

  6. A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

    The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Birmingham Clinical Research, Birmingham, Alabama
    Locations
    157 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07282600 on ClinicalTrials.gov

  7. A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

    The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Birmingham Clinical Research, Birmingham, Alabama
    Locations
    187 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07392190 on ClinicalTrials.gov

  8. AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

    The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the trea…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Univ of Alabama Birmingham, Birmingham, Alabama
    Locations
    74 in total
    Run by
    Novo Nordisk A/S

    See if you can join NCT07533175 on ClinicalTrials.gov

  9. Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

    The primary objective of the study is to determine the effects of ribupatide (KAI-9531) subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Kailera Clinical Site, Birmingham, Alabama
    Locations
    104 in total
    Run by
    Kailera

    See if you can join NCT07284875 on ClinicalTrials.gov

  10. A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

    This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive eit…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Uni of Alabama at Birmingham, Birmingham, Alabama
    Locations
    303 in total
    Run by
    Novo Nordisk A/S

    See if you can join NCT07564414 on ClinicalTrials.gov

  11. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

    This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Univ of Alabama Birmingham, Birmingham, Alabama
    Locations
    838 in total
    Run by
    Novo Nordisk A/S

    See if you can join NCT07567001 on ClinicalTrials.gov

  12. Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

    Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calo…

    Stage
    Phase 3
    Ages
    18 to 79
    Site
    ACCOMPLISH-1 Research Site, Birmingham, Alabama
    Locations
    71 in total
    Run by
    Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

    See if you can join NCT07654361 on ClinicalTrials.gov

  13. PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis

    Obese individuals have a higher prevalence of nocturnal hypertension and non-dipping blood pressure (BP). These conditions are associated with an increased risk of cardiovascular (CV) events and death. Natriuretic Peptides (NPs) are hormones produced by the heart which directly regulate BP by causi…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Alabama at Birmingham, Birmingham, Alabama
    Run by
    University of Alabama at Birmingham

    See if you can join NCT04971720 on ClinicalTrials.gov

  14. GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study

    Natriuretic Peptides (NP) are hormones produced by the heart, and they have a wide range of favorable metabolic benefits. Lower levels of these hormones are associated with an increased likelihood of the development of diabetes and poor cardiometabolic health. Obese and Black individuals have ~30% …

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Alabama at Birmingham, Birmingham, Alabama
    Run by
    University of Alabama at Birmingham

    See if you can join NCT05216042 on ClinicalTrials.gov

  15. Ketogenic Diets for Weight Loss Maintenance: Impact on Energy Expenditure and Appetite in Individuals With Obesity

    The goal of this clinical trial is to investigate whether a Ketogenic Diet (KD) can increase Total Energy Expenditure (TEE), while benefiting appetite, during weight loss maintenance in reduced-obese individuals.

    Stage
    Not phased
    Ages
    18 to 65
    Site
    University of Alabama at Birmingham, Birmingham, Alabama
    Run by
    University of Alabama at Birmingham

    See if you can join NCT06736028 on ClinicalTrials.gov

  16. CARBON: UAB Cardiovascular Research Biobank

    The UAB Cardiovascular Research Biobank (CARBON) will be a resource that contains biological materials, such as DNA samples, in addition to health and personal information on a large number of people over time. It will be set up so that it can be used in the future as a resource for researchers und…

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Alabama at Birmingham, Birmingham, Alabama
    Run by
    University of Alabama at Birmingham

    See if you can join NCT05067231 on ClinicalTrials.gov

  17. Inspire HER: Inspiring the Heart and Emotions for Radical Health

    Poor heart health puts Black women at risk for a shorter life with more illness than people of any other non-indigenous racial group. We will refine and conduct a randomized, wait-list controlled trial of Inspire HER (a heart health lifestyle intervention for Black women that provides health educat…

    Stage
    Not phased
    Ages
    30 to 79
    Site
    University of Alabama at Birmingham, Birmingham, Alabama
    Run by
    University of Alabama at Birmingham

    See if you can join NCT06966258 on ClinicalTrials.gov

  18. International Weight Control Registry

    The IWCR is a global scientific study aimed at better understanding the opportunities and barriers for reducing the prevalence of obesity by collecting information from people who have experience with weight management in their everyday lives. The investigators seek to gather information on a wide …

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Alabama at Birmingham, Birmingham, Alabama
    Locations
    7 in total
    Run by
    Tufts University

    See if you can join NCT04907396 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.